Antiviral compounds
Specific derivatives of thapsigargin and nortrilobolide address the limitations of current RNA virus treatments by offering effective and safe antiviral activity against RNA viruses through host cell innate responses, overcoming toxicity and resistance issues.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- UNIVERSITY OF NOTTINGHAM
- Filing Date
- 2025-11-27
- Publication Date
- 2026-06-04
AI Technical Summary
Current antiviral treatments for RNA viruses, such as influenza A virus, respiratory syncytial virus, and SARS-CoV-2, face challenges due to rapid emergence of resistance, limited efficacy, and toxicity issues, particularly with compounds like thapsigargin, which require toxic concentrations for antiviral effects.
Development of specific derivatives of thapsigargin and nortrilobolide, represented by Formulae (la), (lb), (Ila), (lib), and (Illa), that exhibit antiviral efficacy against a range of RNA viruses by affecting host cell innate antiviral responses, including endoplasmic reticulum stress, without the toxicity associated with higher concentrations of thapsigargin.
These derivatives demonstrate high antiviral efficacy against RNA viruses, including influenza A virus, respiratory syncytial virus, and SARS-CoV-2, with lower toxicity and higher selectivity indices, enabling safe and effective administration at non-toxic doses, and providing sustained antiviral response with infrequent dosing.
Smart Images
Figure GB2025052601_04062026_PF_FP_ABST